CS Diagnostics Corp. (CSDX)
| Market Cap | 56.25M |
| Revenue (ttm) | 98.73K |
| Net Income (ttm) | 19.39K |
| Shares Out | 249.99M |
| EPS (ttm) | 0.00 |
| PE Ratio | 2,900.29 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 49,271 |
| Open | 0.2450 |
| Previous Close | 0.2490 |
| Day's Range | 0.2250 - 0.2450 |
| 52-Week Range | 0.0360 - 1.6200 |
| Beta | -23.92 |
| RSI | 47.54 |
| Earnings Date | n/a |
About CS Diagnostics
CS Diagnostics Corp. engages in designing, manufacturing, and selling of wellness and medical products in Germany and internationally. The company offers MEDUSA, proprietary surface disinfectant product; and CS-Protect Hydrogel, a tissue spacer gel for use in radiation therapy. The company was formerly known as FlashZero Corp. and changed its name to CS Diagnostics Corp. in August 2023. The company was incorporated in 1996 and is based in Neuss, Germany. [Read more]
Financial Performance
Financial StatementsNews
CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting
CHEYENNE, WYOMING / ACCESS Newswire / October 31, 2025 / CS Diagnostics Corp. (OTCQB:CSDX), is a Wyoming-incorporated company with principal operations in Cheyenne, Wyoming. The Company designs, manuf...
CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering
CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of its Regulation D, Rule 506(c) investment offering (the "Offering"), ma...
CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth
CHEYENNE, WY / ACCESS Newswire / September 24, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) ("CSDX" or "the Company"), a pioneering leader in innovative diagnostic and protective solutions, today announce...
CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market
PARTNERING WITH PAUL & ALBRECHT PATENT LAWYERS CHEYENNE, WYOMING / ACCESS Newswire / September 8, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) is delighted to announce the submission of its CS-Protect Hyd...
CS Diagnostics Corp. Submitted Final Form-10 Registration Statement Draft to the processing team for preparation of Edgardization and filing with the U.S. Securities and Exchange Commission ("SEC")
NEUSS, GERMANY AND CHEYENNE, WY / ACCESS Newswire / July 16, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) is pleased to announce that it has successfully submitted the final draft of Form F-10 registratio...
CS Diagnostics Corp. to Present at the Small Cap Growth Virtual Investor Conference June 26th
DUBAI, United Arab Emirates, June 24, 2025 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX), based in Germany and USA and focused on innovation in Healthcare, today announced that Thomas Fahrhoe...
CS Diagnostics Corp. CSDX to Present at the Small Cap Growth Virtual Investor Conference on June 26, 2025 at 12:30pm EDT
NEUSS, DE / ACCESS Newswire / June 18, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) a global leader in innovative healthcare solutions announced its participation in the Small Cap Growth Virtual Investor ...
CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and i...
OTCQB-CSDX Appoints Lachman Consultants for CS-Protect Hydrogel FDA Approval
CS DIAGNOSTICS CORP. ANNOUNCES THE APPOINTMENT OF FDA CONSULTANTS Innovative tissue spacer technology for cancer radiology treatments CHEYENNE, WY / ACCESS Newswire / March 12, 2025 / CS Diagnostics C...
CS Diagnostics Corp. Announces U.S. Launch of MEDUSA
NEUSS, Germany--(BUSINESS WIRE)--CS Diagnostics Corp. Announces U.S. Launch of MEDUSA.